First Quarter 2006 Sales & Earnings - Friday May 5, 2006
The 1st quarter 2006 sales & earnings will be released at 7.00 am (Paris time) and will be available online at http://www.sanofi-aventis.com.
Ämnen: Haelso-sjukvaard
-
-
TRANSFER OF ALL JAPANESE RIMONABANT RIGHTS TO SANOFI-AVENTIS
As part of its strategy to strengthen its presence in Japan, sanofi-aventis announced today that it has agreed with Astellas Pharma Inc. to accelerate the transfer of all rights to rimonabant in Japan from a joint-venture company held by the two groups to sanofi-aventis.
-
LANMET STUDY SHOWS LANTUS® PLUS METFORMIN TO BE EFFECTIVE AND WELL-TOLERATED IN INITIATING INSULIN THERAPY IN TYPE 2 DIABETES
Achieving good glycemic control with less hypoglycemia and less weight gain
-
TAXOTERE® RECEIVES POSITIVE OPINION
TAXOTERE® RECEIVES POSITIVE OPINION FROM THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE RECOMMENDING APPROVAL IN THE EUROPEAN UNION FOR METASTATIC STOMACH CANCER
-
TAXOTERE® RECEIVES U.S. FDA APPROVAL FOR USE IN ADVANCED STOMACH CANCER
TAXOTERE®-based regimen demonstrates a 23% reduction in the risk of mortality in patients with advanced stomach cancer
-
New therapy significantly reduces risk of repeat heart attack and death
Brigham and Womens Cardiac Group Finds Enoxaparin Strategy is Better Than Commonly Administered Blood Thinning Strategy For Heart Attacks - New therapy significantly reduces risk of repeat heart attack and death
-
Agreement between sanofi-aventis and Roche
Shikimic acid is a key raw material for the manufacture of Tamiflu®s active ingredient
-
FIRST LARGE SCALE INTERNATIONAL PRIMARY CARE STUDY CONFIRMS A HIGH WAIST CIRCUMFERENCE IS INDEPENDENTLY ASSOCIATED WITH CARDIOVASCULAR DISEASE
Results from the IDEA Study Highlight the Rising Worldwide Pandemic of Abdominal Obesity
-
Varannan svensk vill minska sin midja
Om svensken själv får välja är det den tjocka magen som ska bort. 51 procent av svenskarna vill ha smalare midja. En majoritet anger omsorg om hälsan som skäl, inte utseende. Det visar en färsk undersökning från Temo.
-
STUDY ANALYZES GENE THERAPY FOR PATIENTS AT HIGH RISK FOR AMPUTATION
NV1FGF Injection Reduces and Delays Risks of Amputation in Patients with Limb Ischemia
-
CHARISMA: NEW STUDY FURTHERS UNDERSTANDING OF THE ROLE OF DUAL ANTIPLATELET THERAPY IN THE PREVENTION OF ATHEROTHROMBOTIC EVENTS
Results from the CHARISMA trial showed that the combination of the antiplatelet agents clopidogrel and aspirin did not demonstrate a statistically significant reduction in the risk of heart attack, stroke or cardiovascular death compared to placebo and aspirin in a broad population of patients with either established atherothrombotic disease or multiple risk factors for atherothrombotic events.
-
Apidra ® A New Rapid-Acting Insulin Analog is Now Available in the United States for Hyperglycemia in Adults with Type 2 and Type 1 Diabetes
New prandial insulin with the OptiClik® delivery system can work with longer-acting insulins, such as basal insulin Lantus®, providing a complementary approach to glucose control
-
RESCHEDULING OF THE TRIAL DATE IN THE UNITED STATES PLAVIX® LITIGATION
At the request of Apotex and Dr Reddys Laboratories, citing scheduling conflicts for their legal counsels, the U.S. District Court for the Southern District of New York has rescheduled the trial date for the Plavix® patent litigation originally set for April 3, 2006.
-
THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION PUBLISHES THE RIO-NORTH AMERICA STUDY
Paris, France, February 14, 2006 Sanofi-aventis announced that the results of the RIO North America trial were published today in The Journal of the American Medical Association (JAMA). The trial evaluated two-year treatment with rimonabant in overweight or obese patients, many of whom were at increased risk for diabetes and heart disease through the presence of additional risk factors.
-
SANOFI PASTEUR DELIVERS MORE H5N1 VACCINE FOR U.S. GOVERNMENT PANDEMIC INITIATIVES
Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), has delivered more H5N1 vaccine to the U.S. government including investigational doses formulated with an adjuvant.
-
Svenska Cardiologföreningen och sanofi-aventis stödjer forskning rörande prevention av hjärtkärlsjukdomar med utgångspunkt från kända kardiovaskulära och metabola riskfaktorer.
Svenska Cardiologföreningen och sanofi-aventis utlyser ett stipendium om 150 000 kronor inom området kardiometabol risk.
-
MY CHILD MATTERS: LAUNCH OF A MOBILISATION CAMPAIGN AGAINST CHILDHOOD CANCER IN EMERGING COUNTRIES
The International Union against Cancer (UICC) and sanofi-aventis are launching a mobilisation program against childhood cancer in emerging countries, in preparation for World Cancer Day, February 4, 2006.
-
Dynamic growth in 2005 full-year consolidated net sales: up 9.3% on a comparable basis1
Excellent performance from vaccines: up 26.9% on a comparable basis1 2005 adjusted earnings1 guidance raised Approval of Plavix® in Japan
-
PLAVIX® APPROVED IN JAPAN
Paris - January 24, 2006 - Sanofi-aventis (EURONEXT : SAN and in New York NYSE : SNY) announced today that the antiplatelet agent Plavix® (clopidogrel) has been approved for marketing in Japan by the Ministry of Health, Labour and Welfare for the reduction of recurrence after ischemic cerebrovascular disorder.
-
FDA GRANTS PRIORITY REVIEW TO PLAVIXÒ (clopidogrel bisulfate) SUPPLEMENTAL NEW DRUG APPLICATION (sNDA) FOR ADDITIONAL TYPE OF HEART ATTACK
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental new drug application (sNDA) for the antiplatelet agent PLAVIX® (clopidogrel bisulfate) for treatment of patients with acute STsegment elevation myocardial infarction (STEMI).
Visa mer
Loading...